Cardiometabolic Health Congress Debate Will Shed Light on Important Questions in Thrombosis and ACS Management
BOSTON, Oct. 13, 2012 /PRNewswire/ — The pros and cons of newer versus older antiplatelet agents in patients with diabetes, the utility of genetic and platelet function testing, and the value of triple combination antiplatelet therapy will be debated by experts at a perennial favorite Cardiometabolic Health Congress (CMHC) session today.
The “Hot Topics in Thrombosis and ACS” session is moderated by Deepak L. Bhatt, MD, MPH, professor of medicine at Harvard Medical School, chief of cardiology at VA Boston Healthcare System, and senior TIMI investigator at Brigham and Women’s Hospital. It takes place from 8:10 am to 9:15 am today.
Each year Dr. Bhatt chooses two expert panelists to debate the most important issues relating to treating patients with ACS. This year he has chosen Peter Berger, MD, director of the Cardiovascular Center for Clinical Research at the Geisinger Health System, and Matthew Roe, MD, associate professor in the Division of Cardiology at Duke University Medical Center.
“This promises to be an exciting, provocative, and controversial session in which two experts debate what the best choices are in contemporary ACS,” Dr. Bhatt said. As always, CMHC attendees will be able to join in on the discussion.
The 7th Annual CMHC, featuring 64 world-renowned expert faculty, 15 scientific sessions, 16 corporate-supported and corporate-sponsored symposia, and approximately 30 CME credit hours, will convene Oct. 10-13, 2012, in Boston. The event is co-chaired by George L. Bakris, MD; Christie M. Ballantyne, MD; Robert H. Eckel, MD; and Jay S. Skyler, MD, MACP. The CMHC provides the most advanced-level cardiometabolic education encompassing a multitude of risk factors, including obesity, Type 2 diabetes, cardiovascular disease, dyslipidemia, atherosclerosis, hypertension, thrombosis, acute coronary syndrome, chronic kidney disease and related comorbidities.
SOURCE Cardiometabolic Health Congress